Why are analysts positive on CSL now?

Valuation has reset after a 34% one‑year fall, while brokers cite improving demand, cost savings, and margin repair. A CMC Markets survey shows 8 Buy and 3 Hold ratings with an A$234 average target, implying about 30% upside if execution holds and guidance on vaccines and plasma is supportive.

When is CSL reporting and what should I watch?

First‑half results are due on 10 February 2026. Focus on flu vaccine demand and pricing, plasma collection volumes and yields, margin guidance, and cash conversion. Any update on Seqirus strategy and capital allocation could shift sentiment and the CSL share price outlook for the rest of FY26.

What is the status of the Seqirus spin-off and why does it matter?

Discussion around a Seqirus spin‑off is paused. Investors want clarity on long‑term strategy, investment needs, and capital returns from the vaccines unit. Updates could impact valuation by changing growth and margin profiles, which in turn influences the CSL share price and the spread of broker targets.

What technical levels are important right now?

Near term, watch A$177.53 as the 50‑day average, A$216.36 at the 200‑day, and Bollinger upper band near A$182.32. Intraday resistance is A$184.62 with support around A$181. A firm close above A$185 could strengthen momentum, while losing A$177 may invite a retest of recent lows.

Global Market Insights

CSL.AX Stock Today: January 28 Analyst Targets Signal 30% Upside

ByDanny Kontos January 27, 2026January 27, 2026

The CSL share price is back in focus after analysts flagged around 30% upside into upcoming results. At A$182.29, CSL.AX rose 2.17% today, yet sits 34.08% lower year on year. A CMC Markets survey points to an A$234 average 12‑month target, while RBC just upgraded to Outperform on valuation. With first‑half numbers due 10 February, we think the CSL share price path hinges on flu vaccine demand, margin recovery, and clarity on Seqirus strategy.